Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 8
---
 of Delaware February
14, 2024, as amended as of the date of this Quarterly Report.

“Class A Common Stock”
refers to the CERo Class A common stock, par value $0.0001 per share.

“Closing” refers
to the closing of the Business Combination.

“Common Warrants”
refers to the Public Warrants, Private Placement Warrants, the Series A Warrants, the Series C Warrants, the December 2024 Common Warrants,
the January 2025 Common Warrants, the February 2025 Common Warrants and the February 2025 Pre-Funded Warrants.

“December 2024 Common Warrants”
refer to the warrants to purchase shares of Common Stock, at a current exercise price of $112.20 per share, issued by the Company in a
private placement on December 23, 2024.

“Earnout Shares”
refer to the Primary Earnout Shares, the Secondary Earnout Shares and the Tertiary Earnout Shares, collectively.

“Exchange Act”
refers to the Securities Exchange Act of 1934, as amended.

“FDA”
refers to the U.S. Food and Drug Administration, or any successor agency thereto.

“February 2025 Common Warrants”
refer to the warrants to purchase shares of Common Stock, at a current exercise price of $39.20 per share, issued by the Company in a
public offering on February 7, 2025.

“February 2025 Pre-Funded Warrants” refer to the warrants to purchase shares of Common Stock, at an exercise price of $0.002 per share, issued in a public
offering on February 7, 2025.

“Fifth PIPE Financing” refers to the
private placement pursuant to which we issued and sold, and certain investors purchased, shares of Series E Preferred Stock, on the terms
and conditions set forth in the Fifth Securities Purchase Agreement.

“Fifth PIPE Registration Rights Agreement”
refers to the Registration Rights Agreement, dated as of October 14, 2025, by and between CERo and certain investors.

“Fifth Securities Purchase Agreement”
refers to the Securities Purchase Agreement, dated as of October 14, 2025, and amended as of October 15, 2025, by and among CERo and certain
investors, pursuant to which CERo agreed to issue and sell up to 9,750 shares of Series E Preferred Stock.

<div align='